Effects of acarbose on polycystic ovary syndrome: A meta-analysis

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 6, 2014, Pages 373-378

  Zhang, Y Y ^a   Hou, L Q ^a   Zhao, T Y ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

acarbose; meta analysis; polycystic ovary syndrome (PCOS)

Indexed keywords

ACARBOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL DISTENSION; ARTICLE; BIBLIOGRAPHIC DATABASE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG EFFECT; FERRIMAN GALLWEY SCORE; HUMAN; LIPID METABOLISM; MENSTRUAL CYCLE; META ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; FEMALE; MEDLINE; POLYCYSTIC OVARY SYNDROME;

ACARBOSE; BODY MASS INDEX; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MEDLINE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE; TRIGLYCERIDES;

EID: 84902687023     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1375676     Document Type: Article

References (22)

1. Gangale M. F., Miele L., Lanzone A. et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol: 2011; 75 520 527
2. Kim J. J., Choi Y. M., Cho Y. M. et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod: 2012; 27 1439 1444
3. Franks S. Polycystic ovary syndrome. N Engl J Med: 1995; 333 853 861
4. Nestler J. E. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol: 1997; 15 111 122 (Pubitemid 27217222)
5. Dunaif A., Scott D., Finegood D. et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab: 1996; 81 3299 3306 (Pubitemid 26296206)
6. Ehrmann D. A., Rosenfield R. L., Barnes R. B. et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med: 1992; 327 157 162
7. Tang T., Lord J. M., Norman R. J. et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility [CD-ROM]. Cochrane Database Syst Rev: 2009
8. Chang C. T., Chen Y. C., Fang J. T. et al. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol: 2002; 15 398 402
9. Geisthövel F., Frorath B., Brabant G. Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study. Hum Reprod: 1996; 11 2377 2381 (Pubitemid 27007437)
10. Laube H. Acarbose: an update therapeutic use in diabetes treatment. Clin Drug Invest: 2000; 22 141 156
11. Salvatore T., Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet: 1996; 30 94 106 (Pubitemid 26069035)
12. Scheen A. J. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab: 1998; 24 311 320
13. Ciotta L., Calogero A. E., Farina M. et al. Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod: 2001; 16 2066 2072 (Pubitemid 32951896)
14. Penna I. A., Canella P. R., Reis R. M. et al. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod: 2005; 20 2396 2401 (Pubitemid 41222483)
15. Penna I. A., Canella P. R., Reis R. M. et al. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. Fertil Steril: 2007; 88 519 522 (Pubitemid 47212130)
16. Tuǧrul S., Kutlu T., Pekin O. et al. Clinical, endocrine, and metabolic effects of acarbose, a α-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. Fertil Steril: 2008; 90 1144 1148
17. Hanjalic-Beck A., Gabriel B., Schaefer W. et al. Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. Gynecol Endocrinol: 2010; 26 690 697
18. Sönmez A. S., Yasar L., Savan K. et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod: 2005; 20 175 179
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril: 2004; 81 19 25
20. Zawadzki J. K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A. (ed.) Polycystic ovary syndrome. Boston Blackwell Scientific: 1992; 377 384
21. Kircher C., Smith K. P. Acarbose for polycystic ovary syndrome. Ann Pharmacother: 2008; 42 847 851 (Pubitemid 351778092)
22. Tauchert S., Schröder A. K., Ortmann O. et al. The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome. Zentralbl Gynakol: 2003; 125 507 514 (Pubitemid 38089707)